NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has initiated in vivo proof of concept studies for its monoclonal antibody, TauC3, in a preclinical model of Alzheimer's disease. The studies are being conducted in collaboration with University of California, Irvine's Dr. Frank LaFerla, Chancellor's Professor and Chair, Neurobiology and Behavior School of Biological Sciences, Director, Institute for Memory Impairments and Neurological Disorders as well as Dr. Kim Green and his team.
"Intellect recently completed additional in vitro characterization of the TauC3 antibody, which was demonstrated to have a high affinity for delta tau," said Dr. Daniel. G. Chain, Intellect's Chairman and CEO. "We also optimized production and produced sufficient quantities to initiate in vivo studies that will include thorough examination of the antibody's effect on neuropathology and behavioral changes in this preclinical model. We look forward to publishing the data later this year."
TauC3 specifically targets the neoepitope that is formed following cleavage of intact tau protein by proteolytic enzymes known as "executioner" caspases. This pathological process is stimulated by an accumulation of amyloid beta in the brain of Alzheimer's patients. It is believed that the smaller cleaved tau, referred to as delta tau, is especially toxic and prone to form tangles inside nerve cells and occurs early in the pathogenesis of the disease so antibody-mediated removal of delta tau would be expected to prevent the irreversible damage to nerve cells.
About Intellect Neurosciences
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com.
The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Quarterly Report on Form 10-Q (file no. 333-128226), filed on November 20, 2012 and the risk factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 15, 2012.
CONTACT: Jules Abraham JQA Partners, LLC 917-885-7378 Jabraham@jqapartners.com
Source:Intellect Neurosciences, Inc.